From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies — Indian drug makers have......
The benchmark indices slumped by around 1% in a volatile session of trade due to the negative triggers from the global front. The looming fears of a slowdown in China, Fed's signals at its latest......
The increasing number of patent litigations in the US against Indian pharma companies and the emergence of patent challengers such as Sun Pharma, Lupin, Orchid and Glenmark are an indication that......
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D. Indian pharma companies’ annual spending on research and......
Indian drugmakers expect a slowdown in new generic drug approvals by the US Food and Drug Administration (FDA) to weigh on sales in their largest market for at least two more quarters, due to an......